Life Sciences

Life sciences companies face unique issues in accessing capital markets, including matters related to due diligence, public relations, regulatory and intellectual property. Goodwin offers a team of sophisticated life sciences lawyers who have expertise with these issues and extensive experience across the full breadth of equity and debt capital markets, advising issuers, sponsors, underwriters and investors in a variety of transactions to ensure deals close smoothly and in a timely way.

Pricing pressure, the reimbursement landscape, eroding margins, low valuations and the tax-friendly political climate are just a few of the factors positioning the life sciences industry for a ramp-up of M&A activity. The climate will be competitive for both buy and sell side prospects, and expert legal advice is critical for companies to be able to seize attractive, strategic opportunities. Thinking about M&A, even as a mere twinkle in your strategic plan? Goodwin can help.

Intellectual property protection is a crucial component for all life science companies. Our life sciences patent lawyers, patent agents and technical staff help assure that the best intellectual property strategy is in place to position and secure intellectual property protection, including patent protection, of our client’s core technology and lead therapeutic moieties, including small molecules, biologics, formulations, delivery systems, companion diagnostics, and medical devices. We have extensive experience in providing intellectual property diligence and assessment of patent landscapes to assist our clients, including operating companies, investors and financial institutions in connection with funding events, including public offerings and private financings, and to solidifying intellectual property positions for acquisition or other exit strategies.

In order to survive and thrive, emerging-growth biotech and specialty pharmaceutical companies depend on the ability to strategically develop, exploit and monetize their intellectual property and product portfolios. Goodwin’s licensing and partnering practice does just that. We offer unmatched counsel and a deep bench of talented lawyers located in biotech, medical and scientific innovation centers throughout the United States.

Companies regulated by the Food and Drug Administration (FDA) know that expertise and practical advice are critical to the bottom line. Goodwin’s experienced FDA practice, a key component of the firm’s Technology & Life Sciences team, provides strategic counseling and skillful advocacy to companies subject to the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, and related federal and state laws. 

Forming, operating and financing an emerging life sciences company can be challenging and time consuming. The experienced lawyers on Goodwin’s Life Sciences team can help guide you through these matters in addition to the varied legal issues that emerging life sciences companies face, allowing you to focus on your core business. With the breakneck pace of technology disrupting industries around the world, and in a highly competitive and fast-paced market, our team has unparalleled experience partnering with emerging life sciences companies ­– from formation through financing to an exit event. In just the last three years the Goodwin Life Sciences team has advised life science companies on over 170 life sciences equity financing deals alone. Our team takes the time to get to know and understand you and your business so that we can better advise you.